Master Research and Collaboration Agreement Sample Contracts
MASTER RESEARCH AND COLLABORATION AGREEMENT by and among JOUNCE THERAPEUTICS, INC. and CELGENE CORPORATION and CELGENE RIVOT LLC Dated as of July 18, 2016Master Research and Collaboration Agreement • December 30th, 2016 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This CELGENE LEAD CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT (this “Celgene Lead Co-Co Agreement”) is entered into and made effective as of [·], 20 (the “Execution Date”) by and among Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Celgene Lead Co-Co Agreement in the United States, and Celgene RIVOT LLC, a Delaware limited liability company (“Celgene RIVOT”), with respect to all rights and obligations under this Celgene Lead Co-Co Agreement outside of the United States (Celgene RIVOT and Celgene Corp. together, “Celgene”). Celgene and Jounce are each referred to herein as a “Party” or, collectively, as the “Parties.”
MASTER RESEARCH AND COLLABORATION AGREEMENTMaster Research and Collaboration Agreement • September 15th, 2016 • Maine
This Master Research and Collaboration Agreement ("Agreement"), effective as [DATE] ("Effective Date") is made by and between The University of Maine System, a body politic and corporate and an instrumentality and agency of the State of Maine acting through the University of Maine ("UMaine") and [Company] ("Company").
MASTER RESEARCH AND COLLABORATION AGREEMENT by and between VIVIDION THERAPEUTICS, INC. and CELGENE CORPORATION Dated as of March 1, 2018Master Research and Collaboration Agreement • June 25th, 2021 • Vividion Therapeutics, Inc. • Pharmaceutical preparations • New York
This Master Research and Collaboration Agreement (this “Agreement”) is entered into as of March 1, 2018 (the “Effective Date”) by and between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
AMENDMENT TO MASTER RESEARCH AND COLLABORATION AGREEMENTMaster Research and Collaboration Agreement • April 30th, 2020 • Agios Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment to Master Research and Collaboration Agreement (this “Amendment”) is entered into as of February 5, 2020 (the “Amendment Date”), by and among Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”), on the one hand, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under the Master Collaboration Agreement (as defined below) in the United States, and Celgene RIVOT Ltd., a Bermuda entity (“Celgene RIVOT”), with respect to all rights and obligations under the Master Collaboration Agreement outside of the United States (Celgene RIVOT and Celgene Corp. together, “Celgene”), on the other hand. Capitalized terms used herein and not defined herein shall have the meanings ascribed to them in the Master Collaboration Agreement.
AMENDED AND RESTATED MASTER RESEARCH AND COLLABORATION AGREEMENT by and among JUNO THERAPEUTICS, INC. and CELGENE CORPORATION and CELGENE RIVOT LTD. Dated as of August 13, 2015Master Research and Collaboration Agreement • August 14th, 2015 • Juno Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED MASTER RESEARCH AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of August 13, 2015 (the “Execution Date”) by and among Juno Therapeutics, Inc., a Delaware corporation (“Juno”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Agreement in the United States, and Celgene RIVOT Ltd. (“Celgene RIVOT”), with respect to all rights and obligations under this Agreement outside the United States (Celgene RIVOT and Celgene Corp., together, “Celgene”). Celgene and Juno are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
MASTER RESEARCH AND COLLABORATION AGREEMENT by and among AGIOS PHARMACEUTICALS, INC. and CELGENE CORPORATION and CELGENE RIVOT LTD. Dated as of May 17, 2016Master Research and Collaboration Agreement • August 8th, 2016 • Agios Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) is entered into as of [•] (the “Execution Date”), by and among Agios Pharmaceuticals, Inc., a Delaware corporation (“Agios”), on the one hand, and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Agreement in the United States, and Celgene RIVOT Ltd., a Bermuda company (“Celgene RIVOT”), with respect to all rights and obligations under this Agreement outside of the United States (Celgene RIVOT and Celgene Corp. together, “Celgene”), on the other hand. Celgene and Agios are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”.
Vividion Therapeutics, Inc. San Diego, CA 92121 Attn: Chief Executive Officer Re: Addition of Stat3 to Master Research and Collaboration Agreement Dear Sir or Madam:Master Research and Collaboration Agreement • April 23rd, 2021 • Vividion Therapeutics, Inc. • Pharmaceutical preparations
This letter agreement (the “Letter Agreement”) is being entered into by and between Vividion Therapeutics, Inc. (“Vividion”) and Celgene Corporation (“Celgene”), in connection with the Master Research and Collaboration Agreement entered into by Vividion and Celgene dated March 1, 2018 (the “Collaboration Agreement”), pursuant to which Celgene and Vividion agreed to collaborate on the research and development of therapeutics directed against certain targets. Capitalized terms used in this Letter Agreement that are not otherwise defined herein have the meanings set forth in the Collaboration Agreement.
MASTER RESEARCH AND COLLABORATION AGREEMENT by and among ONCOMED PHARMACEUTICALS, INC. and CELGENE CORPORATION and CELGENE ALPINE INVESTMENT COMPANY II, LLC Dated as of December 2, 2013Master Research and Collaboration Agreement • March 18th, 2014 • OncoMed Pharmaceuticals Inc • Pharmaceutical preparations • New York
This MASTER RESEARCH AND COLLABORATION AGREEMENT (this “Agreement”) is entered into and made effective as of December 2, 2013 (the “Effective Date”) by and among OncoMed Pharmaceuticals, Inc., a Delaware corporation (“OncoMed”), and Celgene Corporation, a Delaware corporation (“Celgene Corp.”), with respect to all rights and obligations under this Agreement in the United States (subject to Section 12.14), and Celgene Alpine Investment Company II, LLC (“Celgene Alpine”), a Delaware limited liability company, with respect to all rights and obligations under this Agreement outside of the United States (subject to Section 12.14) (Celgene Alpine and Celgene Corp., together, “Celgene”). Celgene and OncoMed are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.”